The cytokine tumour necrosis factor α (TNF-α) has been shown to play a role in human immunodeficiency virus (HIV) replication by activating transcription of the provirus in both T cells and macrophages. Therefore, agents that block TNF-α-induced HIV expression could have therapeutic value in the treatment of AIDS. We have sought to identify antiviral agents that block TNFα induction of HIV LTR-directed transcription, using a cell-based, virus-free assay system in automated high-throughput screening. HeLa cells were transfected with an HIV LTR-luciferase reporter plasmid and a stable line was isolated in which TNF-α increased luciferase production by two-to threefold. This cell line was used to screen approx-imately 15 000 fungal extracts. An inhibitory activity specific for TNF-α-induced HIV LTR transcription was observed in culture OS-F67406. The active component was isolated and identified as a known metabolite, 3-O-methylviridicatin, by NMR and mass spectrometry. No biological activity has been associated with this compound previously. This compound blocks TNF-α activation of the HIV LTR in the HeLa-based system, with an IC 50 of 5 µM, and inhibited virus production in the OM-10.1 cell line, a model of chronic infection responsive to induction by TNF-α, with an IC 50 of 2.5 µM.
Infection with human immunodeficiency virus (HIV) results in a chronic infection, with an asymptomatic phase lasting for a median period of 7-11 years, until the emergence of the symptoms of AIDS. The ability of HIV to replicate in CD4 + T lymphocytes and monocytes is strongly influenced by immunoregulatory cytokines (for review see Poli & Fauci, 1992; Yamamoto, 1995) . Among these, only tumour necrosis factors (TNFs) α and β have been shown to act as potent activators of HIV replication in both cell types and are believed to play a key role in the control of viral latency. The mechanism of action of these cytokines has been elucidated. TNF-α directly activates transcription of the latent provirus by increasing the binding of the cellular transcription factor NF-κB to the HIV long terminal repeat (LTR), by uncoupling it from its cytoplasmic inhibitor Iκ-B (Osborn et al., 1989; Duh et al., 1989; Okamoto et al., 1989) . Elevated plasma levels of TNF-α have been reported in infected individuals, and increased production of this cytokine has been demonstrated in freshly isolated peripheral blood mononuclear cells (PBMCs) from these patients (Poli & Fauci, 1992) . Taken together, these data suggest that TNF-α represents an important regulator of virus production. Therapeutic strategies aimed either at decreasing the production of TNF-α or blocking its inductive effect on HIV transcription have been pursued (for review see Poli & Fauci, 1992) . Our approach has been to identify antiviral agents that block TNF-α induction of HIV LTR-directed transcription. This has been achieved in an automated high-throughput screening (HTS) mode using a cellbased, virus-free assay system. The screening of 14 758 fungal extracts resulted in the isolation and identification of Antiviral Chemistry & Chemotherapy 9: [149] [150] [151] [152] [153] [154] [155] Isolation and characterization of the fungal metabolite 3-O-methylviridicatin as an inhibitor of tumour necrosis factor α-induced human immunodeficiency virus replication Introduction a known fungal metabolite, 3-O-methylviridicatin, that blocks TNF-α activation of the HIV LTR. This compound also inhibited virus production in a cellular model of chronic infection responsive to induction by TNF-α.
Materials and Methods: Virology

Plasmids
The HIV LTR-luciferase reporter plasmid, pHIVLTRLUCI, was constructed as follows: the plasmid pBC12HIV-IL-2 (Hauber & Cullen, 1988) containing the entire HIV-1 LTR region, as described by Cullen (1986) , was cut with SfiI, blunt-ended with T4 DNA polymerase (Boehringer Mannheim) and then digested with HindIII. The resulting 765 bp fragment was sub-cloned into the reporter plasmid pUV110, cut with SnaBI and HindIII. pUV110 contains the luciferase gene sequences immediately downstream of the HindIII site, as well as a neomycin-resistance cassette containing the neomycinresistance gene under the control of the herpes simplex virus thymidine kinase promoter. The plasmid was propagated in Escherichia coli strain DH5α (Gibco-BRL) and purified using the Qiagen Maxi-Prep kit.
Tissue culture and transfections
HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS. To construct a stable cell line containing the luciferase reporter gene under the control of the HIV LTR, 10 7 HeLa cells were trypsinized, washed twice with DMEM without phenol red, resuspended in 1 ml DMEM without phenol red and mixed with 20 µg pHIVLTRLUCI linearized with XmnI. The cells were electroporated in a BioRad Electroporator apparatus, at 260 V and 960 mF and then seeded into four 10 cm dishes. The transfected cells were allowed to recover for 48 h and then placed under selection in medium containing 800 µg/ml G418 (geneticin; Gibco-BRL). Individual G418-resistant colonies were cloned after 2 to 3 weeks of selection, expanded and analysed for luciferase expression. The clones expressing luciferase were further analysed by Southern blot and a clone, C4, that contained a single unrearranged copy of pHIVLTRLUCI was selected and expanded for use in HTS. Clone C4 was maintained in DMEM supplemented with 10% FCS and 100 mg/ml geneticin.
Screening protocol
HTS was carried out as follows: C4 cells were seeded in 96well plates at a density of 5000 cells/well. The plates were then placed in custom-made HTS trays that hold six plates each. From this point on, all the operations were unmanned. TNF-α (Genzyme) was added 12 h later to a final concentration of 10 ng/ml; compound addition proceeded immediately following the addition of TNF-α to the plates in the trays. The lag was estimated to be 15 min between TNF-α addition and compound addition. Approximately 15 000 MYCOsearch extracts were screened, at a final concentration of N/4. The extracts were incubated with the cells at 37°C for 24 h. Luciferase assays were performed by the addition of luciferase buffer (100 mM Tris-acetate pH 7.9, 20 mM magnesium acetate, 2 mM EGTA, 1% Brij 58, 100 mM 2-mercaptoethanol, 36 mM ATP, 150 mM luciferin), and the plates were read after 5 min on a Dynatech Laboratories ML1000 luminometer. The data from each plate was captured, compared to quality control parameters and evaluated by a data processing network.
Anti-HIV assay OM-10.1 cells were grown in RPMI-1640 with 10% bovine fetal calf serum and periodically stock cultures were exposed to AZT (10 µg/ml) to reduce superinfection of non-productive resting cells expressing CD4. Cells were washed three times in growth medium prior to seeding in Falcon 24-well plates at 10 5 cells/well in the presence or absence of different concentrations of inhibitor. Subsequently, each aliquot of cells received TNF-α (0.5 ng/ml). At 24 h and 48 h post-induction, cell culture medium was removed and analysed for p24 antigen (Coulter). The total number of viable cells were determined after trypan blue staining.
Materials and Methods: Chemistry
Storage of fungus OS-F67406
The organism was grown on a slant medium containing 18 g agar, 10 g malt, 50 mg chloramphenicol, 50 mg novobiocin, and 800 µl of a vitamin solution containing 5 mg biotin, 2 g myoinositol, 200 mg D-pantothenic acid, 200 mg pyridoxone and 200 mg/l thiamine in deionized water. The fungus was stored at room temperature until use.
Fermentation and extraction of fungus OS-F67406
A small portion of the culture was transferred from the slant to a seed tube containing 10 ml of liquid medium incorporating 20 g soypeptone, 20 g dextrose and 10 g yeast extract in 1 l deionized water. The culture was incubated on a rotary shaker with a 2.54 cm (1 inch) throw for 7 days at 200 r.p.m. and 22°C. The contents of the seed tube were then transferred to a flask containing 75 ml of the same medium, and incubated on a rotary shaker as above. Approximately 2 ml aliquots were used to inoculate Nunc plates containing solid medium consisting of 9 g agar, 10 g soy meal and 2.5 g mannitol per 500 ml deionized water. The culture was spread over the entire surface of the plate using a bent glass rod. Plates were incubated in a 22°C cabinet incubator for 11 days. Cultures were stored at -80°C until used. Frozen cultures were lyophilized overnight, and the dried culture was extracted by soaking in 500 ml methanol for 4 h. The solvent was filtered off and dried in a rotary evaporator. This material was used to isolate the active compound.
Isolation of the active component of fungus OS-F67406
The dried methanol extract from a 2 l fermentation of culture OS-F67406Sa (5.5 g) was dissolved in 25% aqueous methanol (200 ml) and extracted with hexane (200 ml×2) and chloroform (200 ml×2) sequentially. The chloroform layer was dried (OS-F67406F2, 400 mg) and separated into 10 fractions on a silica gel flash column eluted with chloroform and a step of chloroform/methanol. Fraction 3 from the silica gel column (OS-F67406 F2-3, 30 mg) was subjected to further purification by HPLC (column, HP ODShypersil; solvents, CH 3 CN/H 2 O from 10 : 90 to 50 : 50 in 20 min; flow rate, 0.5 ml/min; detection, UV 254, 340 nm). The active fractions (t R 13-14 min) were collected and dried to yield 3 mg OSI 2109 as a white powder.
NMR and mass spectrometry
All 1 H and 13 C NMR spectra were recorded in CDCl 3 solution on a Varian-500 spectrometer (500 MHz for 1 H, 125 MHz for 13 C). Chemical shifts are reported in p.p.m. relative to solvent (CDCl 3 : δ H 7.24 δ C 77.0). Both low resolution and high resolution mass spectra of 3-O-methylviridicatin were obtained on a Finnegan MAT-90 spectrometer.
Preparation of viridicatin and analogues
Viridicatin (2) was synthesized from isatin and phenyldiazomethane as previously described by Eistert & Selzer (1962a, b) . Deoxyviridicatin (3) was prepared according to a published procedure (Hino et al., 1989) , by deprotonation of N-acetyl-2-aminobenzophenone. The O, N-dimethylated compound 4 was obtained by treatment of viridicatin (2) using methyl iodide (Austin & Myers, 1964) .
Results
Cell-based HTS
A cell-based HTS assay based on a 96-well plate format was developed to screen for inhibitors of TNF-α-activated HIV LTR transcription in human cells. The assay used the production of luciferase as a read-out. A stable cell line, C4, was constructed by transfection of HeLa cells with an HIV LTR-luciferase reporter plasmid. In these cells, luciferase expression was induced two-to threefold by incubation with 1-10 ng/ml TNF-α. A total of 14 758 fungal extracts were screened using this assay. Fermented fungal cultures, freeze-dried and resuspended in 4% DMSO, were screened at 1 : 4 dilution, relative to original culture volume. Each organism was grown in three different nutrient media, in either solid (agar) or liquid (broth), to maximize metabolite diversity. The effect of inhibitory extracts on the activity of the LTR-luciferase reporter, induced in the C4 cell line exposed to TNF-α, was expressed as the transcription inhibition/induction ratio (TIR). A histogram describing the distribution of the TIR values of the 14 758 samples screened is shown in Fig. 1 . As expected, the effects of the fungal extracts fall within a normal distribution, as the majority of the compounds had no effect on the system, and consequently the results centred around a TIR of 1.0. The extracts that inhibited the HIV LTR-luciferase activity by greater than 60% (TIR <0.4) were re-screened to confirm the HTS result. A peak of inhibitory compounds with a TIR between 0.1 and 0.2 (90% and 80% inhibition, respectively) was observed (Fig. 1) . This fraction of the samples screened was expected to contain specific inhibitors of TNF-α-induced HIV LTR activity as well as non-specific, cytotoxic extracts. To distinguish the cytotoxic extracts from the those specifically targeting TNF-α induction of the HIV LTR, the data were compared to those generated by running the fungal extract library against other cell-based assays using non-related promoter-reporter assays. Only six extracts, all derived from organism number OS-F67406 under different growth conditions, were found to inhibit TNF-α induction of HIV LTR-luciferase activity in a selective manner. These extracts did not inhibit the activity of other cellular promoters tested (human fetal globin, bcr, epidermal growth factor and erythropoietin), and also failed to inhibit the activity of the human cytomegalovirus (HCMV) immediate early promoter (Table 1) .
Isolation and characterization of inhibitory activity
The crude extract from a culture grown in the soybean source medium showed the greatest inhibitory activity. For isolation of the active compound(s), the fermentation of fungus OS-F67406 was reproduced in a 2 l volume. Fractionation was achieved with a combination of silica gel flash column and reverse-phase HPLC, and monitored by luciferase assays with the C4 cell line. HRFAB spectrum of the pure compound provided a molecular ion of 252.1008, suggesting two possible molecular formulae: C 16 H 12 O 3 or C 16 H 14 O 2 N. The UV absorption (λ max 280, 328 nm) and 13 C NMR spectrum indicated that it was an aromatic compound with a conjugated α,β-unsaturated lactam ring (δ 160 p.p.m. for C=O, or an α,β-unsaturated lactone ring) and one methoxyl group (δ 60 p.p.m.). The 1 H NMR spectrum of the active molecule displayed 13 protons, including one methoxyl proton singlet, one exchangeable proton singlet and nine aromatic proton multiplets. The coupling pattern and multiplicities of these aromatic protons suggested that they belonged to two isolated proton-spin systems: H-5 to H-8 in a disubstituted benzene ring (A) and H2′ to H6′ in a monosubstituted benzene ring (C); this was confirmed by a COSY experiment. The chemical shift of C-9 (δ 139 p.p.m.) and the long range correlations between H-7 with C-9 and H-5 with C-4 and C-9 disclosed that benzene ring A fused with the lactam or lactone ring to form a coumarin-like system. The attached CH 3 O group at C3 was confirmed by chemical shift (C-3 at 145 p.p.m.) and the long range correlation between methoxyl protons with C-3. The monosubstituted benzene ring C was connected at the C-4 position, based on the long range correlations between H-2′ and H-6′ with C-4. (Austin & Meyers, 1964) and P. verrucosum (Hodge et al., 1988) . The physical and chemical properties of this compound are listed in Table 2 , and the 1 H and 13 C NMR chemical shift assignments are summarized in Table 3 .
Dose-response of 3-O-methylviridicatin and related compounds
The response of the 3-O-methylviridicatin (1) was concentration-dependent in the luciferase reporter assay in the C4 cells, after 24 h incubation at 37°C. Several analogous compounds from our chemical collection, including synthetically prepared compounds and some related coumarins were also tested in the reporter assay (Table 4) . 3-O-methylviridicatin was the most potent compound tested, with an IC 50 of 5 µM (Table 4) . 7-hydroxy-4trifluoromethylcoumarin (7), and 3-deoxyviridicatin (3) had an IC 50 of 20 µM (Table 4 ). The other compounds tested were inactive (Table 4 ).
Antiviral activity
The inhibitory effect of 3-O-methylviridicatin on HIV replication was tested in the OM-10.1 assay system. OM-10.1 cells, which are chronically infected with HIV, were derived from the promyelocytic line, HL60 (Butera et al., 1991) . These cells have minimum constitutive HIV production, where viral expression can be induced by addition of TNF-α (see Materials and Methods) . This is demonstrated in Fig. 2 , which shows the response of OM-10.1 cells to incubation in the presence or absence of 0.5 ng/ml TNF-α. The cytokine was added after the cells were prepared, as defined in the Methods. Virus production, as measured by the output of p24 core antigen into the culture medium, was markedly increased over the unstimulated control at 24 and 48 h post-incubation ( Fig. 2a ). OM-10.1 cells stimulated in a similar fashion but exposed to different concentrations of 3-O-methylviridicatin at the time of incubation showed a dose-dependent inhibition of p24 antigen production at 24 and 48 h post-incubation (Fig. 2b) . The IC 50 values for 3-O-methylviridicatin determined by linear regression analysis were 2.4 µM (24 h) and 2.5 µM (48 h). The inhibitory effect of 3-O-methylviridicatin was not reversed when the concentration of TNF-α was increased 10-fold (data not shown). Cultures exposed to 0.5 ng/ml TNF-α and treated with 3-O-methylviridicatin showed no signs of cytotoxicity as determined by the number of viable OM-10.1 cells present in each culture at 48 h (Fig. 2b ).
Discussion
The demonstration that cytokines and other immunoregulatory molecules exert substantial regulatory effects on HIV expression in chronically or latently infected cells has stimulated the search for agents that could interfere with HIV gene expression via this mechanism. Several drugs that inhibit HIV LTR activity by blocking the action of NF-κB have been described (for review see Li et al., 1994) . Pentoxifylline, which down-regulated HIV LTR expression in a human monocytic cell line (Fazely et al., 1991; Biswas et al., 1993) , has been shown to decrease TNF-α expression in AIDS patients treated with the drug (Dezube et al., , 1995 , but failed to decrease viral load (Dezube et al., 1995) . Antioxidants, like N-acetyl-cysteine, have also been shown to have antiviral effects in vitro in PBMC stimulated with TNF-α, as well as in cells chronically infected with HIV (Roederer et al., , 1991 Kalebic et al., 1991) . The mechanism involved is related primarily to interference with the activation of NF-κB Schreck et al., 1991) . However, the limitation of antioxidants is that the high concentrations necessary to block NF-κB activation were also shown to have a suppressive effect on immune functions in vitro (Aillet et al., 1994) . Our aim was to identify novel natural products that were not antioxidants or pentoxyfylline or its derivatives but were capable of inhibiting TNF-α induction of HIV expression.
In OM-10.1 cells the fungal metabolite, 3-Omethylviridicatin, inhibited TNF-α induction of the HIV LTR with a consequent restriction in the output of progeny virus in a dose-dependant manner; no effect was observed on the integrity of the host cell. In this model of cytokine induction of viral replication, TNF-α will be expected to influence HIV expression by inducing the binding of the transcription factor NF-κB to tandemly repeated elements in the HIV LTR (Duh et al., 1989; Osborn et al., 1989) .
In addition to the fungal product, 3-O-methylviridicatin, we were able to test several analogous compounds, including viridicatin and coumarins, by the luciferase assay (Table 4 ). Viridicatin (2), which has a free hydroxy group at C-3, was completely devoid of activity. However, significant inhibitory activity was observed when R2 was hydrogen (3, 3-deoxyviridicatin). Therefore, we conclude that potent compounds will contain hydrophobic residues at C-3. Intramolecular hydrogen bonding of the oxygen at C-2 with the C-3 hydroxyl could also be responsible for the lack of inhibitory activity in viridicatin. Methylation at N-1 to give the N,O-dimethyl compound 4 also abolished activity. Only one of the coumarins tested so far, 7hydroxy-4-trifluoromethylcoumarin (7), significantly inhibited TNF-α-induced HIV LTR transcription.
3-O-methylviridicatin (1) has been reported previously by Austin & Myers (1964) , who isolated it from P. puberulum, and by Hodge et al. (1988) , who isolated this compound together with a number of related metabolites from P. verrucosum var. cyclopium. To our knowledge, no pharmacological activity has been previously accorded this compound, although the related viridicatin has been shown to be active against Gram-positive and -negative bacteria, yeasts and fungi, and to affect the growth of rice seedlings (Taniguchi & Satomura, 1970) . Here we report that 3-Omethylviridicatin also has anti-HIV activity, and that the mechanism is the inhibition of the TNF-α activation of HIV LTR transcription. Since TNF-α induces HIV expression by uncoupling the cytoplasmic inhibitor I-κB from the cellular transcription factor NF-κB (Osborn et al., 1989; Duh et al., 1989; Okamoto et al., 1989) , we speculate that O-alkyl or deoxy viridicatin acts in the same signal transduction pathway that leads to NF-κB activation. This may mean that an antiviral strategy based on these structures, with potential to inhibit the cytokine-mediated activation of HIV gene expression, could have a profound effect on viral load when used in combination with reverse transcriptase and/or proteinase inhibitors. 
